The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix

被引:61
作者
Hariri, Jalil [1 ]
Oster, Anne [1 ]
机构
[1] Sonderborg Hosp, Dept Pathol, Sonderborg, Denmark
关键词
p16; negative predictive value; CIN; 1; IN-SITU HYBRIDIZATION; HUMAN-PAPILLOMAVIRUS; SIGNAL PATTERNS; P16; PROTEIN; EXPRESSION; GRADE; MARKER; NEOPLASIA; OVEREXPRESSION; BIOMARKERS;
D O I
10.1097/01.pgp.0000236942.51840.56
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The immunohistochemical expression of p16(INK4a) in formalin-fixed and paraffin-embedded histological sections was evaluated in a retrospective study comprising a low-grade group of 100 cases of cervical intraepithelial neoplasia (CIN) 1, a high-grade group of 50 cases of CIN 2 to 3, and a benign group of 50 cases of normal tissue or benign lesions in the uterine cervix. The cases were consecutive within each group and had a minimum follow-up period of 5 years. Positive reaction for p16(INK4a) was detected in all cases in the high-grade group and in only 3 cases in the benign group. In the low-grade group, a total of 9 cases had to be excluded. The remaining 91 cases in the low-grade group showed positive reaction for p16(INK4a) in 65 cases (71%), including 23 cases that progressed to a high-grade lesion, 36 cases that revealed normal cytological and/or histological picture during the follow-up period, and 6 cases that persisted as CIN 1. A total of 26 cases (29%) in the low-grade group showed negative reaction for p16(INK4a). All but one of these p16(INKa) negative cases in the low-grade group had a benign or normal outcome. This case showed a high-grade lesion in the follow-up period and was probably a high-grade lesion from the beginning and so underestimated as CIN 1. These results reveal that the negative predictive value of p16(INK4a) to predict the outcome of the cases of CIN I is as high as 96%, which strongly suggest an important role of p16(INK4a) in the assessment of this type of lesion.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 27 条
[1]   p16INK4a expression correlates with degree of cervical neoplasia:: A comparison detection of high-risk with Ki-67 expression and HPV types [J].
Agoff, SN ;
Lin, P ;
Morihara, J ;
Mao, C ;
Kiviat, NB ;
Koutsky, LA .
MODERN PATHOLOGY, 2003, 16 (07) :665-673
[2]  
*ASS REPR HLTH PRO, 2000, CLIN P MARCH 2000 AS
[3]   The causal relation between human papillomavirus and cervical cancer [J].
Bosch, FX ;
Lorincz, A ;
Muñoz, N ;
Meijer, CJLM ;
Shah, KV .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265
[4]   P16INK4a as a complementary marker of high-grade intraepithelial lesions of the uterine cervix.: I:: Experience with squamous lesions in 189 consecutive cervical biopsies [J].
Dray, M ;
Russell, P ;
Dalrymple, C ;
Wallman, N ;
Angus, G ;
Leong, A ;
Carter, J ;
Cheerala, B .
PATHOLOGY, 2005, 37 (02) :112-124
[5]   Clonality analysis of archival cervical smears - Correlation of monoclonality with grade and clinical behavior of cervical intraepithelial neoplasia [J].
El Hamidi, A ;
Kocjan, G ;
Du, MQ .
ACTA CYTOLOGICA, 2003, 47 (02) :117-123
[6]  
Evans Mark F, 2003, BMC Clin Pathol, V3, P2, DOI 10.1186/1472-6890-3-2
[7]   Human papillomavirus integration:: detection by in situ hybridization and potential clinical application [J].
Evans, MF ;
Cooper, K .
JOURNAL OF PATHOLOGY, 2004, 202 (01) :1-4
[8]   Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia [J].
Evans, MF ;
Mount, SL ;
Beatty, BG ;
Cooper, K .
MODERN PATHOLOGY, 2002, 15 (12) :1339-1347
[9]   The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia [J].
Galloway, DA ;
McDougall, JK .
SEMINARS IN CANCER BIOLOGY, 1996, 7 (06) :309-315
[10]   P16INK4A immunoexpression and HPV in situ hybridization signal patterns -: Potential markers of high-grade cervical intraepithelial neoplasia [J].
Kalof, AN ;
Evans, MF ;
Simmons-Arnold, L ;
Beatty, BG ;
Cooper, K .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (05) :674-679